Idera Pharmaceuticals Inc (NASDAQ:IDRA) recently presented its new pre- clinical data that demonstrates the ability of the TLR or Toll-like receptor antagonist, IMO-8400, for inhibiting survival and the proliferation of the B-cell lymphoma cells that harbor the oncogenic MYD88- L265P genetic mutation. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was -5.78% in last session and finished the day at $2.77. Traded volume was 3.02million shares in … Continue reading Micro-cap Losers: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Travelzoo Inc. (NASDAQ:TZOO), Homex Development (NYSE:HXM), RadioShack Corporation (NYSE:RSH)